CG Oncology
CGON
62.38
-1.26
-1.98%
CG Oncology
US · CGON
#1929 by market cap
Listed 2024
62.38
-1.26
-1.98%
Live - 5344 symbols - heartbeat 484s ago
· 2026-10-08 04:49
Pre-market
61.56
-1.31%
After-hours
62.38
0.00%
- Market cap
- 5.53B
- P/E (TTM)i
- -23.19
- P/Bi
- 5.37
- EPSi
- -2.08
- Div yieldi
- 0.00%
- 52W posi
- 59%
Reader sentiment
Are you bullish or bearish on CGON?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 84.73, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 5 years
Latest year +254.70% YoY
Margins
- Gross margin
- -15.02%
- Operating margin
- -4,722.13%
- Net margin
- -3,985.02%
Key ratios & quality
- Enterprise valuei
- 4.79B
- Altman Z-Scorei
- 84.73
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 10.36M | 191.00K | 204.00K | 1.14M | 4.04M |
| Gross profit | -- | -- | 204.00K | 1.14M | -607.00K |
| Selling & admin expenses | 4.65M | 6.41M | 9.90M | 33.70M | 73.53M |
| Research & development | 18.32M | 29.03M | 45.75M | 82.10M | 116.64M |
| Operating profit | -12.61M | -35.25M | -55.45M | -114.67M | -190.77M |
| Pretax profit | -12.84M | -35.44M | -48.61M | -88.04M | -161.00M |
| Tax | -- | -- | -- | -- | -- |
| Net profit | -12.84M | -35.44M | -48.61M | -88.04M | -161.00M |
| Basic EPS | -1 | -12 | -16 | -1 | -2 |
| Diluted EPS | -0.55 | -11.71 | -15.65 | -1.41 | -2.08 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 52.00K | 0 | 1.67M | 2.32M | 1.08M | 1.16M |
| Gross profit | 52.00K | 0 | 89.00K | -748.00K | -1.88M | -2.77M |
| Selling & admin expenses | 14.79M | 17.41M | 23.33M | 17.99M | 20.78M | 28.98M |
| Research & development | 27.47M | 31.33M | 27.88M | 29.96M | 43.73M | 54.66M |
| Operating profit | -42.20M | -48.74M | -51.13M | -48.70M | -66.39M | -86.40M |
| Pretax profit | -34.45M | -41.43M | -43.81M | -41.31M | -60.20M | -79.06M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -34.45M | -41.43M | -43.81M | -41.31M | -60.20M | -79.06M |
| Basic EPS | 0 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.45 | -0.54 | -0.57 | -0.51 | -0.71 | -0.90 |
Balance sheet
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total current assets | 58.41M | 147.21M | 194.12M | 754.21M | 759.48M |
| Cash & ST investments | 53.61M | 143.48M | 187.67M | 742.00M | 742.16M |
| Inventory | -- | -- | -- | 0 | 1.57M |
| Total assets | 58.69M | 147.75M | 199.30M | 754.80M | 791.59M |
| Total current liabilities | 5.98M | 15.43M | 14.25M | 21.37M | 30.84M |
| Short-term debt | 3.02M | 9.16M | 217.00K | 186.00K | 915.00K |
| Long-term debt | 12.06M | 6.53M | -- | -- | 3.00M |
| Total liabilities | 18,440,000.00 | 22,570,000.00 | 14,511,000.00 | 21,420,000.00 | 38,990,000.00 |
| Total equity | 40.25M | 125.18M | 184.79M | 733.38M | 752.60M |
| Retained earnings | -45.89M | -81.34M | -129.94M | -217.98M | -378.98M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 701.19M | 673.03M | 695.79M | 759.48M | 1.10B | 1.05B |
| Cash & ST investments | 688.43M | 661.05M | 680.26M | 742.16M | 1.08B | 1.03B |
| Inventory | -- | -- | 1.50M | 1.57M | 1.49M | 1.00M |
| Total assets | 728.18M | 701.45M | 729.91M | 791.59M | 1.14B | 1.09B |
| Total current liabilities | 22.64M | 30.38M | 30.53M | 30.84M | 35.22M | 47.24M |
| Short-term debt | 255.00K | 288.00K | 912.00K | 915.00K | 1.07M | 985.00K |
| Long-term debt | -- | -- | 3.00M | 3.00M | 3.00M | 3.00M |
| Total liabilities | 23,423,000.00 | 31,087,000.00 | 42,270,000.00 | 38,990,000.00 | 43,483,000.00 | 56,537,000.00 |
| Total equity | 704.76M | 670.36M | 687.64M | 752.60M | 1.09B | 1.03B |
| Retained earnings | -252.43M | -293.86M | -337.67M | -378.98M | -439.18M | -518.23M |
Cash flow
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | -13.65M | -29.80M | -45.68M | -78.71M | -132.35M |
| Depreciation & amortization | 10.00K | 15.00K | 17.00K | 32.00K | 1.45M |
| Free cash flow | -13.75M | -29.82M | -45.68M | -78.95M | -132.48M |
| Dividends paid | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 629.47M | 147.45M |
| Ending cash balance | 53.61M | 88.14M | 8.27M | 257.07M | 32.49M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -29.28M | -27.96M | -38.89M | -36.22M | -56.94M | -46.41M |
| Depreciation & amortization | 24.00K | 156.00K | 416.00K | 849.00K | 841.00K | 850.00K |
| Free cash flow | -29.29M | -27.97M | -38.99M | -36.22M | -57.25M | -46.88M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 49.00M | 98.45M | 391.55M | 0 |
| Ending cash balance | 41.47M | 14.62M | 45.15M | 32.49M | 33.70M | 19.64M |
Returns & efficiency
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -28.85 | -21.67 |
| ROA %i | -31.32 | -42.42 | -39.07 | -18.45 | -20.82 |
| ROIC %i | -- | -- | -- | -37.53 | -25.56 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- |
| EBIT margin %i | -119.60 | -18,556.02 | -27,180.88 | -10,067.25 | -4,722.13 |
| FCF / sales %i | -- | -- | -- | -- | -- |
| Current ratioi | 9.78 | 9.54 | 13.62 | 35.30 | 24.63 |
| Quick ratioi | 8.97 | 9.32 | 13.17 | 34.72 | 24.09 |
| Debt / assetsi | 25.78 | 10.79 | 0.23 | 0.03 | 0.89 |
| LT debt / equityi | -- | -- | -- | 0.01 | 0.81 |
| Interest coveragei | -27.47 | -35,442.00 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -52.09 | 176.56 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -16.57 | -20.95 | -24.74 | -21.67 | -20.79 | -26.41 |
| ROA %i | -16.15 | -20.24 | -23.63 | -20.82 | -20.04 | -25.11 |
| ROIC %i | -21.08 | -25.70 | -29.26 | -25.56 | -23.84 | -29.59 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -20,302.27 | -28,546.10 | -8,285.33 | -4,722.13 | -4,238.99 | -4,056.18 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 30.97 | 22.15 | 22.79 | 24.63 | 31.30 | 22.22 |
| Quick ratioi | 30.42 | 21.78 | 22.30 | 24.09 | 30.60 | 21.78 |
| Debt / assetsi | 0.14 | 0.14 | 0.99 | 0.89 | 0.67 | 0.81 |
| LT debt / equityi | 0.11 | 0.11 | 0.92 | 0.81 | 0.60 | 0.76 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 04:49:36 · For reference only, not investment advice and not tailored to your situation.